CRISPR Therapeutics
CRISPR Therapeutics's Overview
CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Utilizing its proprietary CRISPR/Cas9 gene-editing platform, the company aims to disrupt the treatment of diseases at the molecular level. Their diverse pipeline includes programs in hemoglobinopathies (like sickle cell disease and beta-thalassemia, with their first approved therapy CASGEVY™), immuno-oncology, regenerative medicine, and in vivo approaches for cardiovascular and other diseases.
Where is CRISPR Therapeutics's Headquarters?
HQ Function
Serves as the company's global corporate headquarters, overseeing strategic direction, financial management, legal affairs, investor relations, and corporate governance.
Notable Features:
Located in a modern business district in Zug, a city known for its international business environment and as a hub for pharmaceutical and biotech companies.
Work Culture:
The headquarters likely fosters a highly professional, innovative, and collaborative environment, driven by the company's mission to pioneer life-changing therapies. It combines Swiss precision with a global, forward-thinking biotech mindset.
HQ Significance:
The Zug location provides a stable political and economic environment, access to European capital markets, and a favorable framework for international operations and intellectual property management.
Values Reflected in HQ: The headquarters' location and function reflect the company's commitment to global leadership, scientific excellence, ethical responsibility, and strategic growth in the biopharmaceutical industry.
Location:
CRISPR Therapeutics operates with a global footprint, anchored by its corporate headquarters in Zug, Switzerland, and major research, development, and manufacturing facilities in the United States (Boston and Framingham, MA), and clinical operations support in London, UK. This strategically distributed presence enables the company to conduct worldwide clinical trials, engage with global regulatory authorities, foster international collaborations, and prepare for global commercialization of its gene-editing therapies.
Street Address:
Baarerstrasse 14
City:
Zug
State/Province:
ZG
Country:
Switzerland
CRISPR Therapeutics's Global Presence
Boston, Massachusetts, USA
Address: 105 West First Street, Boston, MA 02127, USA
Leverages the rich biotech ecosystem of the Boston/Cambridge area, including access to world-class talent, leading academic institutions, and numerous collaboration opportunities to drive innovation.
London, United Kingdom
Address: 25 Buckingham Palace Road, London, SW1W 0PP, United Kingdom
Facilitates engagement with European regulatory bodies (like EMA), manages clinical trial sites, and supports the expansion of CRISPR Therapeutics' pipeline in Europe.
Framingham, Massachusetts, USA
Address: Manufacturing Facility (specific public street address not consistently disclosed, located in Framingham, MA)
Enhances control over the manufacturing process and supply chain for key therapeutic candidates, ensuring quality and scalability for its innovative gene-edited therapies.
Buying Intent Signals for CRISPR Therapeutics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of CRISPR Therapeutics
As of April 2025, CRISPR Therapeutics' leadership includes:
Investors of CRISPR Therapeutics
CRISPR Therapeutics has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12-15 months, CRISPR Therapeutics has strategically strengthened its executive team with key appointments in commercial, people, development, and legal functions, alongside internal promotions. These changes reflect the company's growth, its focus on advancing a broad pipeline, and preparations for commercialization of its approved and future therapies.
Departures
New Appointments:
Technology (Tech Stack) used by CRISPR Therapeutics
Discover the tools CRISPR Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CRISPR Therapeutics Email Formats and Examples
CRISPR Therapeutics typically uses the [first_initial][last]@[domain] email format (e.g., jdoe@crisprtx.com). This is a common pattern in many corporations, particularly in the biotech sector. Other formats might exist but this is the most frequently observed.
[first_initial][last]@crisprtx.com
Format
skulkarni@crisprtx.com
Example
85%
Success rate
News and media
CRISPR Therapeutics Press Release • May 7, 2024
CRISPR Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
CRISPR Therapeutics announced its Q1 2024 financial results, highlighting ongoing CASGEVY™ launches, progress in its immuno-oncology pipeline with CTX112™ and CTX131™, and advancements in its in vivo programs, including investigational treatments for cardiovascular disease and other genetic disorders....more
CRISPR Therapeutics Press Release • February 14, 2024
CRISPR Therapeutics and Vertex Announce European Commission Approval for CASGEVY™ for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
The European Commission granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy, for treating severe sickle cell disease and transfusion-dependent beta thalassemia in eligible patients. This followed earlier approvals in the UK, US, and other regions....more
CRISPR Therapeutics Presentation / Business Wire • May 10, 2024
CRISPR Therapeutics Showcases Broad Pipeline Progress at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
CRISPR Therapeutics presented new data across its portfolio at the ASGCT 2024 Annual Meeting, including updates on its in vivo programs targeting cardiovascular disease (CTX310™, CTX320™) and its next-generation immuno-oncology candidates, reinforcing the breadth and potential of its gene-editing platform....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including CRISPR Therapeutics, are just a search away.